SUBSEQUENT EVENTS

12 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

Subsequent Events [Text Block]

17.  SUBSEQUENT EVENTS

Management has evaluated subsequent events as of March 18, the date the consolidated financial statements were available to be issued according to the requirements of ASC topic 855.

On October 15, 2020, Dwain Irvin, PhD, MPH joined NovAccess Global Inc. as our chief executive officer, replacing Daniel G. Martin, who had been serving as interim CEO. Mr. Martin remains chairman of the board of directors. Dr. Irvin, age 53, is a published researcher and patent author. Dr. Irvin steps into the CEO role after heading the biotechnology division of Innovest Global, Inc. NovAccess acquired StemVax, LLC from Innovest on September 8, 2020.

On October 21, 2020, L. Michael Yukich joined NovAccess Global Inc. as our fractional chief financial officer, replacing Daniel G. Martin, who had been serving as interim CFO. Mr. Martin remains chairman of the board of directors.

Subsequent to the fiscal year ended September 30, 2020 11,137,850 shares of common stock were issued by the company; including 7,500,000 shares issued to Innovest Global, Inc. related to the acquisition of StemVax, LLC; 1,800,000 shares to our CEO Dwain Morris-Irvin and 200,000 shares to our CFO L. Michael Yukich for services provided; as well as additional 1,340,905 shares for investment in the Company by various private investors, and 296,945 to outside service providers.